Effect of Cabergoline on Cognitive Impairments in Transgenic Drosophila Model of Parkinson’s Disease

(E-pub Ahead of Print)

Author(s): Yasir Hasan Siddique*, Rahul, Mantasha Idrisi, M. Shahid.

Journal Name: Letters in Drug Design & Discovery

Become EABM
Become Reviewer


Background: Parkinson’s disease is a common neurodegenerative disorder characterized by selective loss of dopaminergic neurons in the substantia nigra pars compacta.

Introduction: The effects of alpha synuclein, parkin mutation and pharmacological agents have been studied in the Drosophila model.

Method: The effect of cabergoline was studied on the cognitive impairments exhibited by the transgenic Drosophila expressing human alpha-synuclein in the neurons. The PD flies were allowed to feed on the diet having 0.5, 1 and 1.5 μM of cabergoline.

Result: The exposure of cabergoline not only showed a dose-dependent significant delay in the cognitive impairments but also prevented the loss of dopaminergic neurons. Molecular docking studies showed the positive interaction between cabergoline and alpha-synuclein.

Conclusion: The results suggest a protective effect of cabergoline against the cognitive impairments.

Keywords: Parkinson's Disease, Cabergoline, Drosophila, Dopamine agonist, human alpha synuclein, molecular docking

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1570180817999200514100917
Price: $95